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Role of protein tyrosine phosphorylation on
COX-2 induction in endotoxin-activated
endothelial cells and macrophages: a
comparison with nitric oxide synthase
P. Akarasereenont, J. A. Mitchell, I. Appleton,
C. Thiemermann andJ. R. Vane
The William Harvey Research Institute,
St Bartholomews’ Hospital Medical College,
Charterhouse Square, London EClM 6BQ, UK
Cyclooxygenase (COX) and nitric oxide synthase (NOS)
are two enzymes which have distinct cytokine-inducible
isoforms (COX-2 and iNOS, respectively). Many cytokine
receptors have an intracellular tyrosine kinase domain.
Here, we have used the tyrosine kinase inhibitors,
erbstatin and genistein, to investigate the potential role of
tyrosine kinase activation in the induction of COX-2 and
iNOS caused by endotoxin (lipopolysaccharide; LPS at
1 l.tg/ml for 24 h) in bovine aortic endothelial cells (BAEC)
and J774.2 macrophages. The predominant COX
metabolites, 6-oxo-prostaglandin (PG) Flu (for BAEC) and
PGF2= (for 774.2 macrophages) were measured by
radioimmunoassay under the following experimental con-
ditions: (i) accumulation of COX metabolites from endo-
genous arachidonic acid was measured at 24 h after addi-
tion of LPS (1 lag/ml); (ii) in experiments designed to
measure ’COX activity’, COX metabolites generated by
LPS-activated BAEC or J774.2 macrophages were assayed
after incubation with exogenous arachidonic acid (30 l.tM
for 15 min). Western blot analysis with a specific antibody
to COX-2 was used to determine the expression of COX-
2 protein caused by LPS in cell extracts. Accumulation of
nitrite (measured by the Griess reaction) was used to
measure NOS activity. Erbstatin (0.05-5 l.tg/ml) or
genistein (0.5-50 btg/ml) caused a dose-dependent inhibi-
tion of the accumulation of COX metabolites in the
supernatant of LPS-activated BAEC or J774.2 macrophages.
Erbstatin or genistein also caused a dose-dependent inhi-
bition of ’COX activity’ in both cell types. Western blot
analysis showed that erbstatin (5 btg/ml) or genistein
(50 l.tg/ml) inhibited the expression of COX-2 protein in
LPS activated BAEC and J774.2 macrophages. Erbstatin or
genistein also caused a dose-dependent inhibition of nitrite
accumulation in J774.2 macrophages activated with LPS
(1 btg/ml for 24 h). In contrast to J774.2 macrophages,
BAEC stimulated with LPS did not produce detectable
amounts (< 1 M) of nitrite. These results show that
tyrosine phosphorylation is part of the signal transduction
mechanism that mediates (i) the induction of COX-2 and
iNOS elicited by LPS in J774.2 macrophages, and (ii) the
induction of COX-2 by LPS in BAEC.
Inhibition of the local Shwartzman reaction in
rabbits by CSVTCG, a thrombospondin-derived
hexapeptide
C. E. Burrowes, S. Peers, L. Tran, and B. Beaubien
Allelix Biopharmaceuticals Inc., 6850 Goreway Drive,
Mississauga, Ontario, Canada L4V 1P1
Thrombospondin (TSP) is a multidomain protein involved
in cell adhesion processes through its associations with
CD36 (GPIV, GPIIIb), zfl3, {41, and perhaps other bind-
ing proteins. The CSVTCG motif in TSP is responsible for
TSP binding to CD36, and is reported to mediate tumour
cell adhesion and platelet aggregation. The peptide form
of CSVTCG blocks TSP-induced cell-cell associations. We
were interested in determining whether this peptide might
reduce microvascular pathophysiology, and thus tested it
in a model of dermal thrombo-haemorrhage, the local
Shwartzman reaction (LSR), in rabbits. The LSR was pro-
duced by intradermal injection of endotoxin (preparative
dose) followed by intravenous administration of endotoxin
(provocative dose) 18-24 h later. Haemorrhagic lesions
that developed in the prepared skin sites were quantified
by nlln-labelled erythrocytes.. CSVTCG, at a dose of 1.0
mg/kg, given i.v. 15 min before the provocative dose
induced a dose-dependent inhibition of haemorrhage
(max. 80%,.p < 0.05). The same dose of CSVTCG given i.v.
15 min before the preparatory dose was less effective and,
when given i.d., had no effect on haemorrhage. These in
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vivo experiments indicate that TSP is involved in thrombo-
haemorrhagic events.
Telemetric study of monoiodocetate (MIA)
induced osteoarthritis in rats
D. Chevrier, P. Gegout, C. Guingamp, P. Gillet,
B. Terlain and P. Netter
Department of Pharmacology, URA CNRS 1288, BP184,
54505 Nancy, France
Patients’ handicap is the main point during osteoarthritis
(OA). Telemetry, in automatically recording mobility of
laboratory animals, allows measurement of incapacity dur-
ing experimentally induced OA, especially in rats. As
surgical models are inadapted to telemetry, and after pre-
liminary studies of the impact of various chemical agents
on rats’ mobility, spontaneous nocturnal activity was re-
corded in Wistar rats after i.a. injection of MIA in both
knees.
As a result, noctumal mobility was significantly reduced
in the MIA group (3 mg) when compared with controls
(saline i.a.). Typically, MIA.-induced incapacity advanced in
three phases: day 1-3 marked and acute fall; day 4-14:
recovery; then from day 15, progressive incapacity. This
secondary handicap appears very similar to that observed
in human disease; late and slowly progressive oncoming,
moderate amplitude, aggravation without related inflam-
matory phenomenons (lack of fever and histological
signs). Morphological aspect is in favour of an OA process,
showing cartilate erosions and intense osteophytic prolif-
eration. 35S incorporation was assessed ex vivo in a
centropatellar punch and in the remaining patella. Loss of
centropatellar 35S incorporation seems correlated with the
loss of mobility (similar evolution in three phases). Con-
trasting with this decrease of anabolism in the central
punch, the surrounding cartilage exerted an increased
anabolism (osteophytes formation). Early, but not late
administration, of indomethacin (3 mg/kg/day) reinforced
hypoanabolism in the punch.
Thus, MIA-induced incapacity mimics human OA. As a
predictible factor, handicap profile allows studies of early
markers of OA detectable before installation of a marked
incapacity. In addition, effects of treatments can be studied
depending whether administrated before or after the onset
of this handicap. Further explorations on relationships
between handicap and biochemical changes might lead to
new pharmacological targets.
Beneficial effect of polyclonal anti-Group II
PLA2 antibodies in rat endotoxin shock
Giuseppe Cirino, Maria Rosaria Bucci and Carla Cicala
Department of Experimental Pharmacology,
via Domenico Montesano 49, 80131 Naples, Italy
Endotoxaemia leads to an increase in circulating levels of
extracellular phospholipase A in animal models as well as
in patients with septic shock (Vadas et al., 1992). We have
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tested rabbit polyclonal anti-PLA antibodies raised against
human recombinant secreted non pancreatic PLA2 (Group
II PLAa) and porcine pancreatic PEA (Group PLA) in rat
endotoxin shock. Fall in mean arterial blood pressure
induced by endotoxin (25 mg/kg i.v.; serotype 0127:B8)
was 48_+ 3 mmHg (n 13) while for anti-snp-PLA (0.5
mg/kg) and anti-porc-PLA (0.5 mg/kg) was 28 _+ 3 mmHg
(n 5, p < 0.01) and 45 _+ 10 mmHg (n 4; ns). Anti-snp-
PLA, at the lower dose tested (0.1 mg/kg) was ineffective
while the inhibition achieved with the higher dose (1
mg/kg) was similar to that obtained with the dose of
0.5 mg/kg. From a preliminary study was observed that
maximal reduction in leukocyte platelet and haematocrit
was obtained 4 h after LPS administration. Polyclonal anti-
hnps-PLA2 antibodies at the dose of 0.5 mg/kg prevented
the change in platelet count but not in leukocytes and
haematocrit (figure; the line indicates platelet control
value).
Inhibitory effects of a mouse/human chimeric
anti-TNF antibody on in vitro immune
function
M. R. Dalesandro, C. S. Kinney, B. Frederick,
B. Scallon andJ. Ghrayeb
Pharmaceutical Division, Centocor, Inc., Malvern, PA,
USA
Tumour necrosis factor (TNF) 0t, a cytokine produced by
activated macrophages and lymphocytes, is a known
mediator of both normal and chronic inflammation. Prop-
erties of TNF0t including stimulation of IL-1 and
collagenase are consistent with participation in the
pathogenesis of rheumatoid arthritis (RA). Elevated levels
of TNF{x are found in the synovial fluid and on the
membranes of activated CD4 synoviocytes of RA pa-
tients, cA2, a mouse/human chimeric anti-TNF antibody
composed of the murine variable region joined to a human
,1 constant region, has shown clinical efficacy in the
treatment of RA patients. Scatchard analyses reveal that
cA2 y1 and cA2 Fab bind human TNF with equally high
affinities and WEH1 cytotoxicity assays show that they are
equally efficient at inhibiting TNF0t activity. In vitro assays
showed that cA2 y1 inhibited 60% of human peripheral
blood cell proliferation in response to tetanus toxoid,
mixed lymphocyte culture, or immobilized OKT3 anti-
body. The same molar concentration of cA2 Fab inhibited
304 Mediators of Inflammation vol 3. 1994proliferation by a maximum of 25%. Similarly, cA2 T1
inhibited ToB cell collaboration measured by Ig syn-
thesis more effectively than did the cA2 Fab. Since affinities
and neutralization of cytotoxicity are equivalent for the
cA2 T1 and Fab fragments, we are currently pursuing the
possibility that the greater immunomodulation observed
with cA2 71 reflects a combined ability to neutralize solu-
ble TNF0t and to promote Fc-mediated death of activated
cells expressing membane-bound TNFct.
Therapeutic intervention with mycobacterial
65 kDa heat-shock protein peptide 180-188 in
adjuvant arthritis in Lewis rats
Ulrich Feige and fill Gasser
Ciba-Geigy, Department of Inflammation, R-1056.1.84,
CH-4002, Basel, Switzerland
Adjuvant arthritis (AA) in Lewis rats is induced by an
injection of mycobacteria in oil. AA is a T-cell mediated
disease. Mycobacterial 65 kDa heat shock protein
(hsp65) has been shown to be one of the antigens involved
in the disease process, in fact, hsp65 or peptide 180--188
of hsp65 can be used to protect rats against an arthrito-
genic challenge with mycobacteria. However, therapy
rather than prevention of disease appears to be the appro-
priate goal for intervention with disease in man. Therefore,
we investigated whether peptide 180-188 also exhibits
therapeutic effects in AA. We found that treatment of
rats with 0.1-1.0 mg of peptide 180-188 in incomplete
Freund’s adjuvant i.p. at days 9 and 10 after the
arthritogenic challenge with mycobacteria in oil com-
pletely inhibited the onset of AA (no paw swelling,
weight loss or radiographical changes were present).
Even treatment at days 12 and 13, when clinical symp-
toms of disease (paw swelling and weight loss) were
already apparent, was effective. The extent of bone
destruction was reduced; individual radiographical
scores at day 35 were 0, 0, 15, 72, 78 in peptide 180-188
treated rats and 44, 47, 57, 75, 101, 119 in AA control
rats. The data indicate that immunological interven-
tion with peptide 180-188 brings the disease process to a
halt. This suggests that even in established disease the
immune response is the major driving force of the
disease process.
Protection of human endothelial cells from
the cytotoxic effects of activated granulocytes
by Lazaroids and related Hpophilic
antioxidants
William E. Fleming and Frank F. Sun
Hypersensitivity Diseases Research, Upjohn Labs,
Kalamazoo, MI 49001, USA
The damaging of vascular endothelium by activated
granulocytes is a typical feature of the inflammatory re-
sponse. In vitro human granulocytes (neutrophils or
Abstracts
eosinophils) activated by phorbol myristyl acetate (PMA)
can injure and kill human umbilical vein endothelial
cells (HUVECs). We incubated PMA activated human
granulocytes with 51-chromium labelled HUVECs for 4 h
and determined the extent of cell injury by measuring the
release of radioactivity into the medium. The results
confirmed previous findings that granulocyte-induced
cytotoxicity is iron and passage dependent with re-
spect to the endothelial cells. Since it was postulated
that the granulocyte derived reactive oxygen species
were the predominant cytotoxic agents, we examined the
effects of lipophilic antioxidants such as the lazaroid
U-74006F, vitamin E, the vitamin E analogue U-78517F,
the phenolic antioxidant nordihydroguaiaretic acid, the
iron chelator desferroximine, the antiinflammatory steroids
and the water ,soluble antioxidant pyrrolidine
dithiocarbamate (PDTC) as potential inhibitors of
granulocyte induced endothelial cell cytotoxicity. As
expected, the cytotoxicity was blocked by appropriate
concentrations of lipophilic antioxidants. The results
suggest that lipophilic antioxidants can protect against
granulocyte-induced endothelial cell injury during in-
flammation.
Zymosan induced arthritis, in rats:
pharmacological sensitivity
P. Gegout, P. Gillet, D. Chevrier, C. Guingamp,
B. Terlain and P. Netter
Department of Pharmacology, URA CNRS 1288, BP184,
54505 Nancy, France
Zymosan, a glycan derived from yeast cell wall isa
phlogistic agent activating the alternative pathway of the
complement system and inducing lysosomal enzyme re-
lease from PMNs and macrophages. Since zymosan-
induced arthritis was mainly studied in mice, we have
investigated its course in rats and assessed its inflammatory
profile. Zymosan (2 mg) was injected (on day 0) in the
right (histological and pharmacological assessment) or
both knee joints (actimetry) Studies of patellar cartilage
metabolism were assessed ex vivo through proteoglycan
content and 25S incorporation.
After injection of zymosan, swelling of right injected
joints reached a maximum after 24 h and then decreased.
Functional impairment was maximal the night following
i.a. injection, and then decreased progressively.
Histologically, the arthritis was characterized at day 14 by
a chronic proliferative synovitis eroding cartilage. After an
initial fall of chondrocyte proteoglycan synthesis peaking
on day 2, occurred a transitory resumption on day 4. On
day 20, anabolism of proteoglycans seemed normal, but
proteoglycan content in arthritic patellae was significantly
reduced (-18.6%).
Indomethacin (IND), when given orally from day-l, was
effective on knee swelling only on day 1 and at high dose
(3mg/kg/day) while dexamethasone (DEX, 0.1 and
0.5 mg/kg/day) significantly reduced knee swelling
through the first week. Histological score and locomotor
activity were not improved by IND. In contrast, DEX
Mediators of Inflammation. vol 3. 1994 305IAIS Symposium
significantly reduced histological lesions. The initial fall of
cartilage anabolism was worsened by IND (3 mg/kg). On
the other hand, IND was without influence on reduced
proteoglycan content.
In summary, with regard to its drug sensitivity, it is
likely that zymosan induced synovitis in rats results only
partly from cyclooxygenase activation and mostly from
other phospholipids pathways, i.e. 5-LO, PAF... Thus, this
model of subacute syno.vitis behaves in a similar manner
to rheumatoid arthritis and seems potentially useful to
evaluate anti-inflammatory drugs and potentially antide-
generative (chondroprotective) drugs.
in group II. Compared with CCl4, additional LPS resulted
in still further increases both in respiratory frequency and
heart beat/min. In CCl treated animals we observed an
elevation in serum prostacyclin levels which could be
related to the high amount of circulating PLA measured.
In the 24th hour of Gel intoxication in the phase of pro-
gressed damage of liver, rats were more sensitive to the
effect of LPS than in an earlier phase in the first hour of
injury.
We suppose that in Gel intoxicated persons the in-
creased sensitivity to endotoxin can be one of the factors
of clinical complications.
Role of nitric oxide in the pathophysiology of
pancreas inflammation
E. Gelpf, G. Hotter, D. Closa and J. Rosell6-Catafau
Molecular Pathology Unit, Dpto. Bioanalitica Mdica,
Centro de Investigaci6n y Desarrollo, CSIC, Barcelona,
Spain
The relationship between nitric oxide production and
prostanoid generation in two pancreas inflammatory pro-
cess: ischaemia-reperfusion in pancreas transplantation
and pancreatitis has been studied. For this purpose male
Sprague-Dawley rats were subjected to pancreas trans-
plantation, after 12 h preservation or acute pancreatitis
induced by intraductal administration of 3.5% sodium
taurocholate. In both cases, the effect of nitric oxide
synthase inhibition with administration of Na-nitro-i-
arginine methyl esther (I.-NAME) (10 mg/kg) was tested.
The results show increases in 6-keto PGFI= TXB and PGE
in pancreatic tissue after transplantation or pancreatitis. In
the case of transplantation, nitric oxide synthase inhibition
reversed all the observed increases, suggesting that
eicosanoid generation in this process would be mediated
in part by a nitric oxide dependent mechanism. In contrast,
in pancreatitis, nitric oxide synthase inhibition only re-
versed the increases in 6-keto PGFI and TXB levels,
suggesting that endothelial and platelet eicosanoid genera-
tion are mediated through an nitric oxide-dependent
mechanism, while acinar metabolites (PGE2) are generated
in response to cell damage.
Effects of endotoxin (LPS) on carbon-
tetrachloride intoxicated rats
J. Gergely, S. Sipka, M. Udvardy, A. Kulcsdr,
Sz. Gomba, L Csipo and Gy. Szegedi
Department of Pharmacology, 23rd Department of
Internal Medicine, 32nd Department of Internal
Medicine, 4Department of Pathology, University
Medical School of Debrecen, Hungary
We have measured the effects of E. coli lipopolysaccharide
(LPS: 40 I.tg/kg) in two groups of male Wistar rats intoxi-
cated with a single dose of carbontetrachloride (CCL:
125 ml/kg). In group 1 LPS was applied 1 h, in group II
24 h after CC14 treatments. Lethality (25%) was found only
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Antipyretic properties of paracetamol in
normal rats and during various models of
inflammation
P. Gillet, I. Cherkaoui, P. Gegout, F. Lapicque,
E. Boccard,* B. Terlain and P. Netter
Department de Pharmacologie, URA CNRS 1288, BP184,
F54505, Nancy; *Laboratoires UPSA, F92500 Rueil
Malmaison, France
Paracetamol is a widely used antipyretic-analgesic drug,
which inhibits cyclooxygenase (COX). Recent data have
suggested the difference of sensitivity of COX, peripheral
or central, constitutive (COX1) or inducible (COX2) to
paracetamol. We have investigated the impact of paraceta-
mol on body temperature (biotelemetry devices) in normal
rats and during prostaglandin-dependent models of
synovitis and fever. Paracetamol was injected i.p. (25; 50;
100; 200 mg/kg) through its prodrug, propacetamol (PRO-
DAFALGAN).
In normal rat, body temperature and activity vary on a
circadian basis. In this nocturnal animal, body temperature
is highest at night and lowest during the day, mainly
mediated by prostaglandins (PG). During day-time the
highest dose of paracetamol (200 mg/kg) resulted in a
slight decrease in body temperature with a maximal effect
(Emax:-0.61C) observed a Tma of 1.75 h. During night-time,
the 200 mg/kg dose only induced a fall in body tempera-
ture (Emax:-l.06C; Tmax: 1.5 h).
Injections of carrageenan in rat knees induced an
acute fever (39C) and nociceptive-induced hypomobility
(-60%). Paracetamol prevented transiently the febrile re-
sponse and induced a dose-dependent fall in body tem-
perature. With the 200 mg/kg dose Ema (-1.27C) was
observed after a Tma of 2 h with an amplitude vs control
batch of about-2.5C. In contrast, paracetamol did not
restore mobility in arthritic rats. Paracetamol administered
in an established yeast-induced fever demonstrated dose-
dependent antipyretic properties, maximal with the
200 mg/kg dose (Emax: -3.11C; Tmax: 2.5 h).
These results demonstrate hypothermic properties of
high doses of paracetamol in normal rats, and antipyretic
properties at therapeutic regimen in inflamed rats. The
magnitude of maximal effect and duration of antipyretic
properties appears related to the degree of activation of
inducible COX. In addition central properties of paraceta-
mol are more marked on central PG (fever) than on
peripheral PG (synovitis with hypomobility).Abstracts
Ultraviolet B-induced inflammatory cytokine
production, in vivo: initial pharmacological
characterization
D. E. Griswold and M. N. Tzimas
Department of Inflammation and Respiratory
Pharmacology, SmithKline Beecham Pharmaceuticals,
King of Prussia, PA 19406-0939, USA
Effects of BIRM 270 on neutrophil functions
A. F. Hoffman, A. G. Graham, J. Watrous, C. A. Homon,
E. David, R. P. DeLeon, R. M. Dinallo, G. Hansen,
E. Mainolfi, R. Rothelein, P. R. Farina and T. P. Parks
Departments of Biochemistry, Analytical Chemistry and
Immunology, Boehringer Ingelheim Pharmaceuticals,
Ridgefield City, CT, USA
Tumour necrosis factor alpha (TNFz) and inflammatory
cell infiltration following ultraviolet B (UVB) irradiation
was studied. Balb/c mice were exposed to UVB irradiation
(10-30 min) using a bank of six Westinghouse FS40
sunlamps (emitting a spectrum from 270-320 nm; 65% in
UVB range). Energy output was 1067 btW/cm2. TNFz was
measured in tissue homogenates using an EIA.
Myeloperoxidase (MPO) enzyme activity was used as a
marker of neutrophil infiltration. A timecourse and dose-
response of UVB revealed a delayed onset of response for
both TNF0t and MPO. Administration of naproxen (20
mg/kg, p.o.) appeared to exaggerate the response to UVB
(122% increase of TNFz, p< 0.01; 15% increase of MPO,
n.s.). In contrast, the phosphodiesterase inhibitor, rolipram
(10 mg/kg, p.o.) significantly inhibited the release ofTNFz
(78%, p< 0.001) and the MPO response (61%, p< 0.001).
This initial characterization of UVB-induced inflammation
suggests a relationship between TNFx release and inflam-
matory cell infiltration and strong regulation of these
events by cyclic AMP.
The modulation of adhesion molecule
expression on endothelial cells by acteoside,
a component ofStachs Steboldii MI’Q
K. Hayashi, T. Nagamatsu and
Y. Suzuki
Meijo University, Nagoya 468, Japan
Recently, it has been indicated that adhesion of leuko-
cytes to endothelial cells play the important role in both
immune and inflammation response. The development of
agent which is able to blunt the adhesion will be very
beneficial to treat a lot of inflammatory diseases. Acteoside
(ACT) inhibited the adhesion of neutrophils to cultured
human umbilical vein endothelial cells (HUVEC) stimu-
lated with tumour necrosis factor (TNF){z and up-regula-
tion of ICAM-1 expression, but not endothelial leukocyte
adhesion molecule-1 on HUVEC, with TNFz, interleukin-
1[3 or phorbol myristate acetate. The inhibitory effect was
not due to the toxicity of acteoside to HUVEC. On the
other hand, ACT did not increase the amount of
soluble ICAM-1 in the culture medium of HUVEC treated
by TNFz, nor affected the interaction of ICAM-1 and
BBIG-11 (anti-human ICAM-1 monoclonal antibody).
The present data suggest that ACT is promising as an anti-
inflammatory agent in a new category.. Now, we are
investigating the effect of ACT on ICAM-1 expression
by thrombin which do not mediate the de novo syn-
thesis of ICAM-1.
Neutrophils are phagocytes which play a major role in host
defence by emigrating from the blood compartment into
sites of injury or infection where they release
proinflammatory mediators and bactericidal agents. Re-
cently, we identified a compound, BIRM 270, which po-
tently inhibited the biosynthesis of LTB by calcium
ionophore A23187-stimulated neutrophils. The compound
was found to act by blocking the release of arachidonic
acid. The present investigation was conducted to further
define the effects of BIRM 270 on lipid mediator
biosynthesis and various other neutrophil functions, some
previously linked to arachidonate mobilization.
Ionophore-stimulated arachidonate release and platelet ac-
tivating factor biosynthesis (PAF), quantified by GC/MS,
were inhibited similarly by BIRM 270, with > 90% inhibi-
tion achieved at 30 nM and half-maximal inhibition at
about 14 nM. BIRM 270 did not affect any other neutrophil
responses investigated, including: chemotaxis; Mac-1 ex-
pression (from mobilization of secretory vesicles); adher-
ence to activated endothelium; lysozyme release (from
degranulation of specific and azurophilic granules);
lactoferrin release (from specific granules); or the genera-
tion of superoxide radical, as measured by the reduction of
cytochrome C in the presence or absence of superoxide
dismutase. We conclude that the actions of BIRM 270 are
restricted to the biosynthesis of lipid mediators, and that
arachidonate may not play an important second messenger
role in other neutrophil functions, e.g. NADPH oxidase
activation. In addition, our results provide pharmacological
evidence that arachidonate mobilization and PAF
biosynthesis may be coordinately linked.
Methyl arachidonyl fluorophosphonate, a
potent irreversible cPLA inhibitor, blocks the
mobilization of arachidonic acid in human
platelets and neutrophils
Z. Huang, S. Liu. I. Street, F. Laliberte, K. Abdullah,
S. Desmarais, Z. Wang, B. Kennedy, P. Payette,
D. Riendeau, P. Weech and M. Gresser
Merck Frosst Centre for Therapeutic Research. P.O. Box
1005, Pointe-Claire, Dorval, Quebec, Canada, H9R 4P8
Methyl arachidonyl fluorophosphonate (MAFP) was de-
signed as a cPLA inhibitor based on its preference for
arachidonyl moiety and the possible involvement of a
serine residue in its active site. MAFP wax found to be a
potent time-dependent irreversible inhibitor of cPLA2. It
inhibited cPLA stoichiometrically in vitro with an esti-
mated kon of 0.9 s
-1 mol fraction
-1 on the 4 mol% DTEPM/
Triton X-100 mixed micellar interface in the presence of
calcium. Preincubation of cPLA2 with the reversible inhibi-
tor AACOCF (arachidonyl trifluoromethyl ketone) pro-
tected cPLA,, from MAFP, indicating AACOCF3 competes
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with MAFP. Whereas the human secreted 14-kDA
phospholipase A (sPLA2) was not inhibited by MAFP at
concentration as high as 10 mol%. Thus, MAFP is a potent
selective active-site directed inhibitor of cPLA2. MAFP was
not an inhibitor for human 5-1ipoxygenase when tested at
10 btM (--30 mol%) in vitro; however, it inhibited the
A23187-induced production of LTB in human neutrophils
with a IC50 of--- 0.1 btM. Furthermore, MAFP blocked the
A23187-induced AA release with a ICs0 of 0.6 btM in the
presence of ETYA in human platelet. MAFP also inhibited
A23817-induced 12-HETE (IC50 0.61aM) and TxB (IC50
0.6 l.tM) production by platelets. In contrast, it did not
inhibit 12oHETE and TxB production in platelets when
exogenous AA was used as a stimulus instead of A23187
(IC50 > 10 I.tM). These results indicate that MAFP is a potent
inhibitor capable of blocking the production of AA in
neutrophils and platelets, cPLa might be involved in
A23817-induced mobilization of AA in neutrophils and
platelets. The identical ICs0S for inhibition of AA, TxB and
12-HETE production in platelets suggest that TxB and 12-
HETE were derived from the same pool of AA.
Platelet-derived growth factor (PDGF) and
angiotensin II (AII) stimulate the mitogen-
activated protein kinase cascade in renal
mesangial cells
A. Huwiler,1 S. Stabel," D. Fabbro and J. Pfeilschifte
1Department of Pharmacology, Biozentrum, Switzerland;
2Max-Delbrtick-Labor, K{51n, Germany; 3Pharmaceuticals
Division, Ciba-Geigy Ltd, Basel, Switzerland
Treatment of mesangial cells with PDGF and AII rapidly
and dose-dependently stimulated mitogen-activated pro-
tein (MAP) kinase activity. Whereas stimulation with
PDGF-BB caused a potent and sustained (for more than
30 min) phosphorylation and activation of p42TM and
p44mapk as well as of the upstream activators MAP kinase
(MEK) and c-Raf, the effect of A II was less potent and
peaked at 5-10 min and thereafter declined rapidly.
Down-regulation of protein kinase C (PKC)-x and-8
isoenzymes by 4 h or 8 h treatment with phorbol 12-
myristate 13-acetate (PMA) markedly inhibited PDGF-
induced MAP kinase activation. Exposure to PMA for 24 h,
a regimen that also depletes PKC-, did not further reduce
the level of activation by PDGF-BB, suggesting that both
PKC-dependent and PKC-independent pathways are in-
volved in PDGF-stimulated MAP kinase activation. A II-
stimulated MAP kinase activity was decreased by 60% after
8 h of PMA treatment, a time period that caused complete
down-regulation of PKC4z and-& In contrast to PDGF a
24 h treatment with PMA completely abolished A II-stimu-
lated MAP kinase activity indicating that PKC- substan-
tially contributes to A II-stimulation of the MAP kinase
pathway. Activators of protein kinase A, such as forskolin
or N, 2’-O-dibutyryl-cAMP, attenuated PDGF- and A II-
stimulated MAP kinase activation.
In summary, these results suggest that PDGF-BB and
angiotensin II differ in their potency and duration of
activating of the MAP kinase cascade which may explain
why PDGF-BB is a potent mitogen for mesangial cells
whereas A II only triggers mesangial cell hypertrophy.
Regulation and expression of prostaglandin
G/H synthase in U937 cells
J. J. Johnston and J. M. Trzaskos
The DuPont Merck Pharmaceutical Company,
Inflammatory Diseases Research, P.O. Box 80400,
Wilmingt6n, DE 19880-0400, USA
Prostaglandin G/H synthase catalyses the rate limiting step
in the production of prostaglandins from arachidonic acid.
Inhibition of this enzyme by non-steroidal anti-inflamma-
tory drugs (NSAIDs) has proven useful in the treatment of
inflammatory conditions, however, mechanism-based GI
and renal side effects are observed with most NSAIDs.
Recently, an inducible form of PGHS has been discovered
which is thought to be the major contributor to prosta-
glandin production during inflammation. In order to more
completely define the contribution of this isoform to in-
flammation, an understanding of the expression patterns
of both PGHS genes is necessary. We have shown that
numerous agents including serum, TPA, LPS, and TNF-0t
can induce the expression .of PGHS2 mRNA in fibroblasts
while having minimal effects on PGHSl expression. Using
luciferase reporter gene constructs containing between
600 bp and 2 kb of the murine PGHS2 promoter region,
luciferase activity can be induced by serum, while TPA, IL-
l and TNF-z do not show an effect. When these reporter
gene constructs are transfected into the monocytic U937
cell line they are responsive to TPA, showing a ten-fold in-
crease in luciferase activity upon TPA stimulation. The
inability of TPA to act through the promoter region in
fibroblasts, coupled with the lack of clear AP-1 elements in
this region of PGHS2 suggests that a monocyte specific
factor may be responsible for the TPA response seen in
U937 cells.
Tetrahydrobiopterin is a limiting factor of
nitric oxide generation in interleukin
l[-stimulated rat glomerular mesangial cells
H. Mahl and J. Pfeilschifter
Department of Pharmacology, Biozentrum, University of
Basel, Basel, Switzerland
Treatment of mesangial cells with recombinant human
interleukin 1[3 (IL-1[3) triggers the expression of a
macrophage-type of nitric oxide (NO) synthase and the
subsequent increase of cellular concentratign of cGMP and
nitrite production. Tetrahydrobiopterin (BH4) is an essen-
tial cofactor for NO synthase and in the present study we
investigated its impact on inducible NO synthesis in
mesangial cells. Inhibition of GTP-cyclohydrolase i, the
rate-limiting enzyme for BH4 synthesis, with 2,4-diamino-
6-hydroxy-pyrimidine (DAHP) potently suppresses IL-lJ3-
induced nitrite production and elevation of cellular cGMP
levels. This inhibitory effect of DAHP is reversed by
sepiapterin, which provided BH4 via the pterin salvage
pathway. Most importantly, sepiapterin dose-dependently
augments IL-lJ3-stimulated NO synthesis, indicating, that
the availability of BH4 limits the production of NO in
cytokine-induced mesangial cells. N-acetylserotonin, an
inhibitor of the BG4 synthetic enzyme sepiapterin
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reductase, completely abolishes IL-lJ3-stimulated nitrite
production, whereas methotrexate, which inhibits the
pterin salvage pathway, displays only a moderate inhibi-
tory effect, thus suggesting that mesangial cells predomi-
nantly synthesize BH4 by de novo synthesis from GTP. In
conclusion, these data demonstrate that BH4 synthesis is
an absolute requirement for, and limits IL-1 13 induction of
NO synthesis in mesangial cells. Inhibition of BH4 synthe-
sis may provide new therapeutic approaches to the treat-
ment of pathological conditions involving increased NO
formation.
Anti-inflammatory effect of BMS-181162, a
PLA inhibitor on two animal models of
immune modulated inflammation
X. Nair, L. Davern, C. Gabrel, P. Stanley and
K. Tramposch
Dermatology Research, Buffalo, NY, USA
BMS-181162, a known inhibitor of PLA2, is active against
models of immune modulated inflammation, viz. The re-
verse passive arthus (RPA) model in rats and the delayed
type hypersensitivity model in mice (DTH). The inflamma-
tory response in the RPA model is precipitated by immune
complex deposition, and c0mplement-fixation, with PMN
infiltration, and vascular permeability increase. Vascular
permeability was measured by the accumulation of 125I-BSA
in tissue and PMN infiltration was measured by
myeloperoxidase (MPO) activity in the reaction site. BMS-
181162 in a Tween 80/normal saline (0.5/99.5) vehicle was
dosed i.p. 2 h before the administration of anti-BSA and
BSA. Drug effect was measured 4 h post antigen/antibody
administration. The DTH reaction in mice was induced by
topical application of oxazolone. BMS-181162 was applied
topically to the ear and PMN infiltration was measured by
MPO activity. In the RPA model BMS-181162 caused a
dose-dependent inhibition of vascular permeability and
PMN infiltration. BMS-181162 at 50 mg/kg also significantly
inhibited PGE2 and LTB increases. In the DTH assay BMS-
181162 (2%) reduced PMN infiltration in the inflamed ear
by 63%. It is significant that this PLA2 inhibitor has demon-
strated activity against two models of immune modulated
inflammation following systemic and local administration.
These results suggest the potential for developing agents
that are active against both immune complex and cell
mediated inflammation.
Demonstration and characterization of anti-
inflammatory activity in a carbohydrate
(glycogen) extract of the New Zealand
green-lipped mussel
D.J. Ormrod, J. R. Dodd, R. Geddes and T. E. Miller
Departments of Medicine and 1Biochemistry, University
of Auckland, Auckland, New Zealand
Many effective modern drugs were originally derived from
plants or animals. In the past two decades there has been
renewed interest in the search for pharmaceuticals in
nature. The marine environment, with its huge and
diverse reservoir of species, has received particular
attention. Many potentially effective compounds have
been isolated, but few have been used clinically.
However, in cases where the parent organism can be
economically harvested or farmed, nutraceuticals with
apparent clinical benefits have reached the market-
place. Freeze-dried NZ green-lipped mussel (Perna
canaliculus), marketed internationally as Seatone(C), is
one example (McFarlane Laboratories, Auckland, New
Zealand). Laboratory and clinical investigations have
shown that this preparation inhibits experimentally in-
duced inflammation and may provide symptomatic
relief in individuals with arthritis. We have studied the
mollusc in an effort to identify the active moiety. Our most
recent results demonstrate that the activity resides in a
glycogen fraction of the mussel. The extract effectively
reduces carrageenin-induced inflammation in rats, follow-
ing either oral or parenteral administration. The com-
pound also suppresses neutrophil emigration, possibly
by blocking carbohydrate receptors on neutrophils or
endothelial cells.
Transcriptional activation of lipocortin-1
L. Parente, F. Russo-Marie and E. Solito
I.R.I.S. Siena, Italy and II.C.G.M. Inserm U332, Paris,
France
Lipocortin-1 (annexin-1) is a member of a family of pro-
teins with calcium and phospholipid binding properties
which is a putative mediator of the anti-inflammatory
action of glucocorticoids. Since controversial data have
been reported on the capability of steroids of inducing the
synthesis of lipocortin-1 we have studied the promoter
region of 880 bp of the protein gene which contains the
first not translated exon and the first intron. Different cell
lines (HeLa, U-937, A-549) wee transfected with a plasmid
containing the luciferase reporter gene under the control
of the lipocortin-1 promoter. Transient expression of the
reporter gene was enhanced by phorbol 12-myristate 13-
acetate (PMA, 10 nM), dexamethasone (DEX, 1 t.tM), and
IL-1 (500 pg/ml). Interestingly the stimulatory effect of
PMA was counteracted by a short incubation (2 h) with
DEX while it was potentiated by a long treatment (16 h)
with the glucocorticoid. These results indicate that
glucocorticoids are indeed able to enhance gene expres-
sion of lipocortin-1. The inhibitory effect of 2 h DEX on
PMA-stimulated gene expression may be explained by
interference with AP-1 activity, which is induced by PMA,
by direct intereaction or by DNA binding. The synergistic
effect of 16 h DEX may be due to phosphorylation by PMA
of transcription factors interacting with the glucocorticoid
receptor.
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Detection of soluble ICAM-1, cytokines (IL-I,
IL-6, TNF0 and eicosanoids (LTB4, PGE2, TXB2,
6kPGFI) in ascites of patients with portal
hypertension, peritoneal cancer and
spontaneous bacterial peritonitis
w. M. Pruimboom, D. J. Bac, L L. Bonta, J. H. P. Wilson
and F. J. Zijlstra
Pharmacology and Internal Medicine, Erasmus
University, Rotterdam, The Netherlands
human platelets by binding of aggregating agents, e.g.
platelet activating factor or ADP.
The mechanism of Syndetoxin
R action is the simultane-
ous binding, absorption of several types of toxic agents or
toxins. This character of SDTX can be very advantageous
especially.in septic or other types of shock where lots of
toxic substances are produced and sustaining the
pathologic state.
Ascites is a complication of portal hypertension and of
peritoneal cancer. Spontaneous bacterial peritonitis (SBP)
is a serious complication in these patients. We measured
soluble ICAM-1 (sICAM-1), several cytokines (interleukin-
1[3 (IL-1[3), IL-6 and tumour necrosis factor-0t (TNF-00) and
several eicosanoids (LTB4, PGE2, TXB and 6kPGFI) in
ascites and serum from patients (54) with cirrhosis (alco-
holic, viral, PBC and other causes), peritoneal cancer (26)
and SBP (10) to determine whether the pattern of media-
tors found could be of diagnostic and/or prognostic aid.
Ascitic sICAM-1, the cytokine IL-6 and the eicosanoids
LTB and PGE2 were significantly elevated in peritoneal
cancer compared with portal hypertension. Ascitic IL-6 was
significantly elevated in SBP compared with portal hyper-
tension and peritoneal cancer. There was a positive corre-
lation (p< 0.001) between serum and ascites sICAM-1
levels, but not for the other metabolites. During SBP there
was a significant increase in ascitic slCAM-1 and IL-6 (not
in serum), which rapidly declined after antibiotic treat-
ment.
Conclusion: There are significant differences in concen-
trations of inflammatory products in ascites due to different
disorders, but none of these mediators seems to be useful
as a diagnostic parameter as there is an overlap between
all the levels of these mediators in ascites. SlCAM-1 and IL-
6 could be of prognostic aid for patients with SBP, as the
episodes of infection correlate with the levels of these
mediators.
SyndetoxinR binds phospholipase A, tumour
necrosis factor and endotoxin, and
significantly decreases the lethality of
endotoxtn shock in rats
S. Sipka, G. Bot, P. Gergely, L. Bali, P. Sdpy,
J. Csongor, L. Bert6k and G. Szeged
13rd Department of Internal Medicine, 2Department of
Medical Chemistry, 3Central Isotope Laboratory, 42nd
Department of Surgery, University of Debrecen,
STRIGON Laboratory, 6National Research Institute for
Radiology, Budapest, Hungary
Syndetoxin
R (SDTX) is a semisynthetic, non toxic
biopolymer which dose-de.pendently binds la5I-labelled
human secretable phospholipase A2 (14 KD), 25I-labelled
human recombinant tumour necrosis factor and 99mTc
labelled E. coli lipopolysaccharide (endotoxin). 10 mg/kg
i.v. pretreatment of rats with SDTX result in a 60% survival
of animals sensitized by Pb acetate for the 100% lethal dose
of endotoxin. SDTX has still an antiaggregatory effect on
Pharmacologic efficacy of LY293111, a potent
orally active leukotriene B4 (LTB) receptor
antagonist, in humans
S. M. Spaethe, P. Marder, L. L. Froelich,
B. H. Petersen, T. W. Croghan, R. A. Lucas, T. Tannera
and J. s. Sawye#
1Lilly Research Laboratories, Indianapolis, IN, USA; 2Lilly
Research Centre, Windlesham, UK; Simbec Research
Ltd, Merthyr Tydfil, South Wales, UK
A common element of inflammation is the accumulation
and activation of leukocytes at inflammatory foci. These
events are directed by biological mediators, including
LTB4. Among the various physiological changes that
neutrophils (PMNs) undergo during activation is an in-
crease in the number of the adhesion receptors, CDllb/
CD18, on the cell surface as measured by flow cytometry.
Pre-incubation of human PMNs, either isolated or residing
in whole blood with LY293111 prevents the subsequent
upregulation of CD11b in response to LTB4. We applied
this technique to evaluate the pharmacodynamic profile of
LY293111 in man. Volunteers received either LY293111 or
placebo orally, and sequential blood samples were taken
and challenged ex vivo with Egg (10 nM). The degree of
CD11b receptor upregulation was measured over time for
each subject. There was marked inhibition (>73%) of LTB4-
induced CD11b expression on whole blood PMNs from
volunteers receiving either 60 or 120 mg t.i.d., or 200 mg
b.i.d. 8-12 h after dosing. This inhibition was reversible
upon termination of dosing. Additional studies demon-
strated the selectivity of LY293111 utilizing an alternative
agonist, fMLP, in these same subjects following the high
dose of LY293111. We conclude that LY293111 has potent,
selective pharmacologic activity in man. These observa-
tions could provide the basis for novel therapeutic treat-
ments of human inflammatory diseases.
Activation of human eosinophils by cytokines:
differential expression of adhesion/activation
markers and potentiation of survival by
chemokines
G. E. Winterrowd, F. F. Sun, C. A. Ha’eld,
W. E. Fleming, N.J. Crittenden, I. M. Richards and
J. E. Chin
Upjohn Laboratories, Kalamazoo, MI 49001, USA
We have examined by flow cytometric analysis the differ-
ential induction of a panel of adhesion/activation markers
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on normal human peripheral blood eosinophils by
IL-3, IL-5 and GM-CSF after 18 h and 48 h of in vitro
culture. The expression of CDlla, CD11b, CDllc and
CD18 were increased 18 h and 48 h after activation
by all three cytokines at 10 ng/ml. Of the cytokines
tested, IL-3 had the most pronounced effect when
compared with IL-5 and GM-CSF. CD49b, CD49e and
CD49f were found on very few of the inactivated
eosinophils, but CD49d and CD29 were present on >90%
of these cells. Expression of the J31 integrins remained
unchanged even after 48 h of incubation. All of the
eosinophils expressed CD44, CD58 (LFA-3), CD45RO,
CD67, CD9, CD63 and CD31 but the mean channel
fluorescence (MCF) of these antigens (except for CD31
and CD63) was elevated by IL-3, IL-5 and GM-CSF.
The percentage of eosinophils which expressed CD25,
CD69 and CD54, and the MCF were both increased
by these cytokines. Conversely, the expression of L-
selectin was dramatically reduced by cytokine treat-
ment (IL-3>>IL-5=GM-CSF). RANTES, MCP-1, or MIP-10t/[
(all at 20 ng/ml) did not alter the expression of any
of the eosinophil cell surface antigens. Furthermore,
these chemokines did not potentiate the effect of IL-3
or IL-5. RANTES, MCP-1, or MIP-Iz/[3 alone did not
prolong the survival of eosinophils even when the cells
were placed on laminin, Collagen Type or IV, and
fibronectin-coated plates. However, the prolongation of
eosinophil survival by IL-3, was enhanced by the addi-
tion of chemokines. Potential cytokine and chemo-
kine interactions may contribute to the pathophysiology
of eosinophilic inflammation.
Involvement of CD36 in acUte lung
inflammation and injury in IgG immune
complex-mediated rat lung injury
z.-J. Yang, C. Black and B. Beaubien
Allelix Biopharmaceuticals Inc., Mississauga, Ontario,
Canada L4V 1V7
CD36 is a cell surface receptor for thrombospondin (TSP),
and has been determined to mediate significant effects of
TSP on cell adhesion and platelet aggregation. Since el-
evated TSP levels have also been demonstrated in inflam-
matory sites (JImmunol 1989; 143: 1969-73), we investi-
gated the role of CD36 in acute lung inflammation using
a rat model of IgG immune complex-induced alveolitis (J
Clin Invest 1974; 54: 349-357). To generate the immune
response, rats were given bovine serum albumin (BSA)
intravenously and anti-BSA IgG intratracheally. Four hours
later, the following parameters were measured: total cell
numbers, cell differentials, haemoglobin concentrations in
bronchoalveolar lavage (BAL), plasma extravasation in
BAL, and plasma exudation in perfused lungs. Monoclonal
antibodies (Mabs) directed against human CD36 (OKM5
and MCA722) induced a dose-dependent inhibition of
airway leukocyte infiltration, haemorrhage and plasma
exudation. The two Mabs were approximately equipotent.
Intratracheal administration of the same dose of Mab was
more effective than an intravenous dose. Isotype control
immunoglobulins had no effect. These findings demon-
strate for the first time that CD36 is involved in lung
damage in this model.
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